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Abstract: The use of plant‐derived natural products for the treatment of tropical parasitic diseases 27 
often has ethnopharmacological origins. As such, plants grown in temperate regions remain largely 28 
untested for novel anti‐parasitic activities. We describe here a screen of the PhytoQuest Phytopure 29 
library, a novel source comprising over 600 purified compounds from temperate zone plants, 30 
against in vitro culture systems for Plasmodium falciparum, Leishmania mexicana, Trypanosoma evansi 31 
and T. brucei. Initial screen revealed 6, 65, 15 and 18 compounds, respectively, that decreased each 32 
parasite’s growth by at least 50% at 1‐2μM concentration. These initial hits were validated in 33 
concentration‐response assays against the parasite and the human HepG2 cell line, identifying hits 34 
with EC50 <1 μM and a selectivity index of >10. Two sesquiterpene glycosides were identified 35 
against P. falciparum, four sterols against L. mexicana, and five compounds of various scaffolds 36 
against T. brucei and T. evansi. An L. mexicana resistant line was generated for the sterol 700022, 37 
which was found to have cross‐resistance to the anti‐leishmanial drug miltefosine as well as to the 38 
other leishmanicidal sterols. This study highlights the potential of a temperate plant secondary 39 
metabolites as a novel source of natural products against tropical parasitic diseases. 40 
Keywords: Drug Discovery; Neglected Tropical Diseases; Natural Products; Temperate zone; 41 
Leishmaniasis; African Trypanosomiasis; Surra; Malaria 42 
 43 
1. Introduction  44 
The Neglected Tropical Diseases (NTD) represent a diverse group of communicable diseases 45 
identified by the World Health Organisation (WHO) that cause significant morbidity and mortality 46 
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amongst the poorest one billion people globally [1,2]. These diseases include viral, bacterial and 47 
parasitic diseases that share common challenges around the lack of investment in the development 48 
of new therapeutics to replace current treatments that may be affected by widespread resistance, poor 49 
tolerance due to toxicity and complicated, expensive and sometimes lengthy regimens. With future 50 
challenges around climate change along with an advocacy for a One Health approach integrating 51 
human and animal health with their environment, the importance of harnessing all our resources for 52 
drug development are pressing [3–5]. 53 
Natural products from plants have always been an important source of treatments for human 54 
disease – with records for the use of plant‐based medicines found within the earliest records of 55 
humans to almost half the modern pharmacopeia being derived from natural products [6–9]. For 56 
tropical parasitic diseases, this impact is illustrated by the isolation of the active pharmaceutical 57 
quinine from the bark of the cinchona tree [10–13]. Whilst plant‐based traditional medicine provides 58 
the basis for the success of many ethnopharmacological studies, a key limitation of this approach is 59 
that the search for treatments primarily focuses on plants indigenous to disease endemic regions.   60 
The Phytopure library [14] represents a unique resource for the screening of anti‐parasitic 61 
activity in the aetiological agents of human and animal tropical diseases. The library consists of 62 
compounds purified primarily from over 60 temperate zone plant families and represents a diverse 63 
range of plant secondary metabolite classes. Around two thirds of the compounds represent novel 64 
compounds not available in other commercial libraries. With some evidence for antiviral and 65 
antimicrobial action for compounds in the Phytopure library, this study set out to evaluate the 66 
potential for this novel resource as anti‐parasitics. This study focused on three parasites from the 67 
Trypanosomatidae family (Leishmania and Trypanosoma species) representing our research interests 68 
in the search for new lead compounds to seed drug discovery efforts for the devastating human and 69 
livestock diseases they cause. In addition, the apicomplexan parasite Plasmodium falciparum, the 70 
aetiological agent of the most severe form of human malaria, was included to diversify the scope of 71 
the tropical parasitic diseases investigated. 72 
Leishmaniasis is a spectrum of diseases caused by infection with the parasite Leishmania spp. 73 
which is transmitted by the bite of female sand flies. Leishmaniasis is endemic in 97 countries across 74 
the globe, with over 270,000 new cases reported to WHO in 2018 [15]. There are 3 main forms of the 75 
disease, depending largely on the species of parasite. The most severe form is visceral leishmaniasis 76 
(VL) or kala‐azar, in which the parasites invade the liver and spleen; this condition is usually fatal 77 
unless treated. The most common form of the disease is cutaneous leishmaniasis (CL) which accounts 78 
for more than 75% of all cases. CL results in skin lesions which can take many months to heal, may 79 
be highly stigmatising and can leave permanent scarring [16]. A complication of CL is muco‐80 
cutaneous leishmaniasis (MCL) in which parasites invade and cause destruction of mucous 81 
membranes, particularly in the face and neck [16]. Treatment of all forms of leishmaniasis depends 82 
on the use of a small number of drugs which are largely expensive, toxic and difficult to administer. 83 
The pentavalent antimonials (e.g. meglumine antimonate) remain the first line treatment for CL 84 
despite high toxicity and resistant parasites emerging. The first line drug for VL in India is ambisome 85 
[17], a liposomal formulation of amphotericin B which shows reduced toxicity compared to the 86 
standard drug but is extremely expensive. Other options include miltefosine, pentamidine and 87 
paramomysin. Miltefosine is the only oral treatment for leishmaniasis but has teratogenic activity and 88 
so is contraindicated for pregnant women, and there have been major challenges in drug supply [18–89 
20].  90 
Human African Trypanosomiasis (HAT) is a vector‐borne disease endemic to rural and 91 
impoverished areas of sub‐Saharan Africa. The causative agents of HAT are the subspecies of the 92 
parasite Trypanosoma brucei; specifically, T. b. gambiense and T. b. rhodesiense in West and East Africa, 93 
respectively. Control of the disease has been highly successful over the last 2 decades, with a decrease 94 
in new cases reported to WHO of 95% between 2000 and 2018 [21]. The decrease in cases will likely 95 
continue with the recent introduction of fexinidazole [22], the first orally available drug against 96 
T. b. gambiense. However, treatment of central nervous system (CNS) infection by T. b. rhodesiense still 97 
relies on melarsoprol, which is painful to administer and results in death of ~5% of patients from the 98 
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treatment alone [23]. The subspecies T. b. brucei is non‐infective to humans, is genetically tractable in 99 
the laboratory and has been used extensively as a model organism to study biogenesis and structure 100 
of organelles such as the flagellum and Golgi apparatus [24,25]. 101 
While there has been a large decrease in African trypanosomiasis in humans, infection due to 102 
African trypanosomes is still a considerable issue for livestock production. Surra is a major veterinary 103 
disease of livestock which is caused by the dyskinetoplastic parasite Trypanosoma evansi. Directly 104 
evolved from and closely related to T. brucei, T. evansi has lost the majority of its mitochondrial DNA 105 
and lacks the ability to carry out mitochondrial respiration [26]. The parasite is mechanically 106 
transmitted by biting insects, particularly tabanids and stomoxes [27]. This mechanism of 107 
transmission has enabled the parasite to spread beyond the African tsetse belt to the Middle East, 108 
North Africa, South East Asia and Latin America [28,29]. The parasite has a very broad host range 109 
and causes a wasting disease in camels, equines and dogs. While Surra is an economically devastating 110 
disease, it has not received as much attention as the human infective Trypanosoma species. The most 111 
common treatment, diminazene aceturate, has poor efficacy and tolerance in some animal species 112 
(e.g. horses) and has been used on livestock for decades, with resistant parasite strains now emerging. 113 
New effective therapies are urgently needed for this disease [27]. 114 
Human malaria falls outside of the NTD group, with significant efforts over recent years 115 
resulting in the introduction and continued development of new antimalarial drugs [30,31]. 116 
Increasing evidence of drug resistance against the frontline artemisinin combination therapies [32], 117 
however, highlights the demand for the continued search for new chemical classes to seed the drug 118 
discovery pipeline.  119 
 This study set out to evaluate whether the PhytoQuest Phytopure library could act as a source 120 
of novel anti‐parasitic leads. In doing so, the aim is to establish the potential of temperate zone plant 121 
natural products, a relatively uncharacterised source of leads for tropical parasitic disease research, 122 
as a novel resource in the fight against parasitic diseases. 123 
2. Results and Discussion 124 
2.1. Screening the PhytoQuest Phytopure library for growth inhibition identifies multiple hits across different 125 
parasites 126 
634 compounds from the PhytoQuest Phytopure temperate plant natural product library were 127 
screened for growth inhibitory activity against L. mexicana axenic amastigotes, T. brucei bloodstream 128 
form, intraerythrocytic asexual P. falciparum (at 2 μM) and T. evansi bloodstream form parasites (at 129 
1 μM). Figure 1 summarizes the results across all parasites using a heatmap where the most potent 130 
compounds are represented in dark grey/black and the least potent in light grey (see Table S1 for raw 131 
data). Our initial hits were defined as reducing growth of the parasite by ≥50%.  132 
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 133 
Figure 1: Heatmap of PhytoQuest Phytopure temperate natural product screen against protozoan 134 
parasites. 634 compounds were screened against L. mexicana (L.m) axenic amastigotes, T. brucei (T.b) 135 
bloodstream form and P. falciparum (P.f) intraerythrocytic trophozoites at 2 μM and T. evansi (T.e) 136 
bloodstream form parasites at 1 μM. Survival (reported as % of DMSO control) of each parasite cell 137 
line is represented as a spectrum from black to light grey (see scale to right), with the black cells 138 
reporting hits taken forward in this study. Blank cells indicate where no data was collected for that 139 
compound. 140 
For L. mexicana this threshold was reduced to inhibiting growth by ≥80% survival due to the 141 
large number of hits (64 in total) using the ≥50% criteria. A total of 14 compounds were therefore 142 
taken forward as initial hits against L. mexicana, including four sterols (700022, 700107, 700136, 143 
700240), seven sesquiterpenes (700756, 701154, 701155, 701157, 701158, 701159, and 701212) and three 144 
aromatic diynes (701044, 701241, and 701248). Of these 14 compounds, seven were identified as an 145 
initial hit in at least one of the other three parasite species in this screen.  146 
There were 18 initial hits against T. brucei, including three flavonoids (700585, 700586, 701082), 147 
four bisobolane sesquiterpene glycosides (700035, 700042, 700046, 700048); six additional 148 
sesquiterpenes (701154, 701155, 701156, 701157, 701158, 701159), an abietane diterpenoid (700014), an 149 
aromatic diyne (701241), an iridoid monoterpene (701145), a coumarin (700867) and a glycoside 150 
(700004). Of these 18 hits, nine were active against at least one other parasite species in the screen.  151 
The T. evansi screen yielded 15 initial hits, including three sesquiterpenes (701155, 701157, 152 
701158), two bisobolane sesquiterpene glycosides (700042, 700046), two abietane diterpenoids 153 
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(700063, 700454), a terpenoid glycoside (700458); two flavonoids (700326, 701088), a sterol (700016), a 154 
glycoside (700004) and a lignan (700144). Of the 15 hits, six were identified as an initial hit in at least 155 
one of the other three parasite species in this screen. Of particular note, despite the close phylogenetic 156 
relationship of the two Trypanosoma genus parasites in the screen, only six compounds were 157 
identified as initial hits in both T. brucei and T. evansi. These were five sesquiterpenes (701155, 701157, 158 
701158), including two bisobolane sesquiterpene glycosides (700042, 700046), as well as the glycoside 159 
(700004).  160 
The P. falciparum screen identified eight initial hits, six of which were sesquiterpenes (700535, 161 
701158) with four of these being bisobolane sesquiterpene glycosides (700042, 700046, 700048, 162 
700104). Of the eight hits, five were identified as an initial hit in at least one of the other three parasite 163 
species in this screen.  164 
The total number of compounds identified as having growth inhibitory activity in at least one 165 
parasite species was 38/634, equating to 6% of the PhytoQuest Phytopure library (Figure 2, Figure S1, 166 
Table S2). Of these 38 compounds, 71% were terpenes with all four parasites showing sensitivity to 167 
multiple terpenoids. This is unsurprising, as terpenoids, and sesquiterpenes in particular, have 168 
previously been reported to have broad anti‐plasmodial and anti‐kinetoplastid activity [33,34]. For 169 
example, the sesquiterpene 701158, isolated from Arnica montana (commonly known as Mountain 170 
Tobacco) was identified as a hit in all parasite screens. Similarly,  bisobolane sesquiterpene 171 
glycosides isolated from Phyllanthus acuminatus, and similar in structure to the phyllanthostatins 172 
[35,36], were identified as initial hits against all parasites in this study except L. mexicana. The abietane 173 
diterpenoids 700014 and 700063 were identified in the T. brucei and T. evansi screens, respectively, 174 
and represent a class of plant‐derived natural product known to have a wide range of growth 175 
inhibitory activity against L. donovani, L. major, and P. falciparum [34,37,38]. Whilst neither 700014 or 176 
700063 showed activity against P. falciparum, they did decrease L. mexicana survival by some 70% and 177 
thus fell just below the selection threshold.  178 
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Figure 2: Structures of compounds which had <1 μM activity against the relevant parasite cell line, 180 
with an SI of ≥10.  181 
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The rearranged abietane diterpenoid 700454, which was identified in the T. evansi screen, is 182 
constitutionally identical to the previously identified leriifoliol [39]. Stereochemistry has not been 183 
assigned in this study, and thus it is unknown whether they are identical stereochemically. 184 
Interestingly, leriifoliol has previously been isolated and tested against protozoan parasites, 185 
exhibiting micromolar activity against T. b. rhodesiense and submicromolar activity against 186 
P. falciparum [39]. However, in our screen 700454 only reduced P. falciparum growth by 5%. 187 
Understanding whether this could be due to 700454 having divergent stereochemistry to leriifoliol 188 
that affects the growth inhibitory activity against P. falciparum, or whether the difference occurs as a 189 
result of the use of the multidrug‐resistant Dd2Luc strain in the screen, compared to the drug sensitive 190 
NF54 strain in the original report, could be useful in terms of understanding any target. 191 
Four of the lanosterone‐like sterols (700022, 700107, 700136, 700240) only inhibited growth in 192 
L. mexicana. Similar sterols, such as pistagremic acid, have also shown leishmanicidal activity [34,40] 193 
and have also been implicated in lipase and anticancer activity [41,42]. Interestingly, 700016, another 194 
lanosterone‐like sterol, was effective against T. evansi and decreased L. mexicana survival by more 195 
than 50% (Table S1). The predominant structural difference between the leishmanicidal and 196 
trypanocidal sterols is that the lactone headgroup, a 3‐methyl‐2(5H)‐furanone in 700016 is replaced 197 
instead with a 5‐hydroxy‐3‐methyl‐2(5H)‐furanone in 700022, 700107 and 700136 and a ring‐opened 198 
lactone in 700240 (Figure 2, Figure S1). The absence of the 5‐hydroxy group appears to increase the 199 
activity of these sterols in T. evansi, relative to a decrease their activity in L. mexicana. Abies procera 200 
derived lanosterone‐like sterols from the PhytoQuest Phytopure library have previously been 201 
identified as potent inhibitors of the helminth parasites Schistosoma mansoni and Fasciola hepatica [43], 202 
highlighting this class of molecule as a potential lead for multiple parasitic diseases.  203 
2.2 Demonstrating selectivity of these anti-parasitic hits 204 
Initial hits from the parasite panel screen were taken forward in log concentration versus 205 
normalised response assays to estimate the half maximal effective concentration (EC50) in hit species 206 
as well as the half maximal cytotoxic concentrations (CC50) in the human hepatoma cell line HepG2 207 
as a preliminary test for selectivity. Using CC50/EC50 to define the selectivity index (SI), the selectivity 208 
for each compound in a defined species compared to a human cell line was estimated and compared 209 
to the EC50 (Figure 3). From this analysis, the application of new thresholds (EC50<1μM and an SI of 210 
≥10) was used to refine the hits for each parasite species (Table S3).  211 
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 212 
Figure 3: Comparison of potency and cytotoxicity of hit compounds. Comparison of the EC50 to the 213 
selectivity index (SI) of hit compounds in A L. mexicana, B T. brucei, C T. evansi and D P. falciparum. 214 
The SI reports the CC50 of the compound in HepG2 cell line divided by the EC50 of the reported 215 
parasite line. The grey dotted lines indicate the preferred potency and SI (≥10) thresholds, with hits 216 
taken forward from the top left quadrant only. The green box highlights the potential lead compounds 217 
that fall within these thresholds.  218 
The four lanosterone‐like sterols derived from the Noble Fir Abies procera (700022, 700107, 219 
700136) and the Grand Fir Abies grandis (700240) were the only initial compounds taken forward for 220 
L. mexicana due to their nanomolar activity and apparent low cytotoxicity (Figure 3 a). Of these 221 
sterols, 700240 was the least potent. Understanding the impact of the ring‐opened lactone head group 222 
in this compound compared to the other three warrants further analysis in exploring their structure‐223 
activity relationships. These four sterols were also tested for growth inhibitory activity against 224 
L. donovani axenic amastigotes. The similar potency of their growth inhibitory activity (Figure 4 a) 225 
suggests they may have a broader leishmanicidal activity beyond that reported here for L. mexicana. 226 
As Leishmania spp. amastigotes typically reside with macrophages, further cytotoxicity assays with 227 
these sterols were performed against an activated monocyte cell line (THP‐1) (Figure 4 b). The sterols 228 
generally had CC50 >20 μM providing SI of >20, although they were more cytotoxic against THP‐1 229 
than HepG2 cell lines (Table S3, Figure S2). Following the observations made above for the ring‐230 
opened lactone head group in  700240, this compound also had the lowest potency of these four 231 
sterols in L. donovani and the lowest selectivity (SI of 21) against THP‐1 (CC50 of 13.5μM) cell lines.  232 
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 233 
Figure 4: Sterol activity against two Leishmania species and an activated monocyte cell line. A Mean 234 
EC50 (μM) of the reported sterol compounds against L. donovani and L. mexicana axenic amastigotes. 235 
Error bars represent upper limits of the 95% confidence interval. B EC50 values (left axis) and 236 
selectivity index (SI, right axis) of the same sterols against an activated monocyte cell line (THP‐1). 237 
Error bars represent upper limits of the 95% confidence interval for the EC50 and the SI represents the 238 
selectivity of these compounds against L. mexicana compared to THP‐1. 239 
Five compounds were identified with acceptable selectivity and submicromolar activity in 240 
T. brucei (Figure 3 b). These were three bisobolane sesquiterpene glycosides (700035, 700046 and 241 
700048), the iridoid monoterpene (701145) and the flavonoid (700585). Further analysis of 700046, 242 
700048 and 700585 was not conducted as, whilst the preliminary selectivity against HepG2 was >10, 243 
the actual CC50 was <10 μM and suggested a general toxicity risk (Table S3). Compound 701145 is an 244 
iridoid monoterpene with a deaminated tyrosine (Figure 2) that was isolated from Bogbean, 245 
Methyanthes trifoliata, with an EC50 and CC50  of 0.52 μM and 27.8 μM, respectively. Compound 246 
700035 was the least cytotoxic of the bisobolane sesquiterpene glycosides (HepG2 CC50 of 15.2 μM) 247 
although it is apparently quite potent with an EC50 of 0.35 μM. 700035 was isolated from the Jamaican 248 
Gooseberry tree Phyllanthus acuminatus and is very similar to the previously synthesised (+)‐249 
Phyllanthocin 3 [35]. The structural variation is an acetate group on the second sugar being on C4 in 250 
700385 rather than on C3 in (+)‐Phyllanthocin 3. Of the bisobolane glycosides identified in this screen, 251 
700035 is the only one with a ring‐opened epoxide, suggesting that this motif warrants further 252 
investigation, particularly in T. evansi and P. falciparum.  253 
Five of the T. evansi initial hits were indicated for further analysis, although the bisobolane 254 
sesquiterpene glycoside 700046 was discounted due to the demonstrated intrinsic HepG2 255 
antiproliferative activity (Figure 3 c, Table S3). Both 700144 and 700513 had low or no detectable 256 
growth inhibitory activity in HepG2 up to 100 μM. Compound 700144 is a lignan isolated from 257 
Hewittia sublobata (Figure 2), with some similarities in structure to other lignans such as arctigenin 258 
and matairesinol, which are known to have broad antiproliferative activity [44–46]. 700144 activity is 259 
likely different to that of arctigenin, however, as the latter exhibits a potent antiproliferative activity 260 
against HepG2 cells [47]. Lignans similar to 700144 have been shown to have in vitro activity against 261 
L. donovani axenic amastigotes, T. b. rhodesiense and P. falciparum, though not at the levels of potency 262 
observed here against T. evansi [48]. Compound 700513, a labdane‐like diterpenoid compound 263 
isolated from the tropical lilac Cornutia grandiflora (Figure 2, Table S2), displayed similarly promising 264 
potency and selectivity towards T. evansi. While not as selective as 700144 and 700513, the flavonoid 265 
glycoside 701088 (Figure 2) also exhibited high levels of growth inhibition in T. evansi and selectivity 266 
against HepG2 (Figure 3 c). This class of compound has previously been reported to have both 267 
antiviral and antimalarial activity, as well as having an important role as a secondary metabolite in 268 
the oak tree Quercus ilex [49–51]. The glycoside 700004 (Figure 2) satisfied the thresholds of potency 269 
and selectivity, adding to the structural diversity of the T. evansi potential leads identified in this 270 
study (Figure 3 c). 271 
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The three compounds that demonstrated potency and selectivity for P. falciparum were 272 
bisobolane sesquiterpene glycosides (700046, 700048, 700104) (Figure 3 d). The potency of these 273 
compounds was also tested against the more sensitive P. falciparum 3D7 strain, and found to have 274 
similar sub‐micromolar activity with 700046 being the most potent in both strains (Figure 5 a). To 275 
further explore the pharmacodynamics of their activity the initial rate of kill was determined using 276 
the bioluminescence relative rate of kill (BRRoK) assay [52,53] and compared to the rates of kill for 277 
atovaquone (ATQ, slow killing compound with 48hr lag in action) and dihydroartemisinin (DHA, 278 
rapid initial rate of kill with no lag in action) (Figure 5 b, Table S4)[52]. All three bisobolane 279 
sesquiterpene glycosides had a similar initial rate of kill (Figure 5 c, Table S4). This is not surprising 280 
as the rate of kill is a result of the mechanism of cell death and, given their structural similarity, these 281 
three bisobolane sesquiterpene glycosides likely share the same target(s), albeit with some differences 282 
in affinity. The rate of kill, relatively, falls between that of atovaquone and dihydroartemisinin and 283 
is more similar to that of chloroquine [52,53]. Unfortunately, all three compounds showed intrinsic 284 
toxicity in our preliminary selectivity screen against HepG2 (CC50 of approximately 2 μM,  Table S3) 285 
and were not developed as antiparasitic lead compounds any further.  286 
 287 
Figure 5: Potency and rate of kill of bisobolane sesquiterpene glycoside hits against Plasmodium 288 
falciparum. A Comparison of EC50 values of bisobolane sesquiterpene glycoside hits against 289 
intraerythrocytic P. falciparum Dd2 and 3D7 cell lines. Time course of rate of kill for B control 290 
antimalarial compounds atovaquone (ATQ) representing a slow rate of kill and dihydroartemisinin 291 
(DHA) representing a fast rate of kill. against C the bisobolane sesquiterpene glycoside hits. Time 292 
course data (3, 6 and 48hr) show the normalized bioluminescence signal (compared to an untreated 293 
control at the same timepoint) following exposure to a fold‐EC50 exposure of the indicated compound. 294 
Error bars represent upper and lower limits of the StDev (n=9). See Table S4 for concentrations used.  295 
Whilst sesquiterpenes generally showed submicromolar activity against all the trypanosomatids 296 
screened here, they demonstrated a similar potency against the HepG2 cell line and had a preliminary 297 
SI of <10 in all cases. For example, compound 701158, which was identified as a hit against all 298 
parasites in the initial screen, had a HepG2 CC50 of 0.8 μM, compared to an estimated 1 μM activity 299 
in P. falciparum. The only sesquiterpene that had a CC50 ≥10 μM in the HepG2 cell line was the 300 
bisobolane glycoside 700035. An important lesson from this screen was that a pan‐parasite panel 301 
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activity was almost always associated with toxicity in our preliminary cytotoxicity screens against 302 
HepG2..  303 
Overall, this screen has identified potential lead compounds in L. mexicana, L. donovani, T. brucei 304 
and T. evansi which warrant further investigation. No compounds of interest, however, were 305 
identified against P. falciparum, despite the relatively low stringency of our potency and selectivity 306 
thresholds.  307 
2.3 L. mexicana parasites with resistance to 700022 have cross-resistance to Miltefosine but not to 308 
Amphotericin B 309 
A 700022‐resistant line of L. mexicana (r22) was generated using a previously reported method 310 
[54] (Figure S3). Briefly, promastigote parasites were cultured with 700022 over 28 weeks, with 311 
incremental increases in compound concentration as the EC50 in promastigotes increased from 312 
11.5 μM to 85.6 μM in promastigotes (Figure 6 a) and from 0.24 μM to 10.1 μM in axenic amastigotes 313 
(Figure 6 b). All leishmanicidal sterols identified were assayed against r22 after 8 weeks of 700022 314 
pressure and cross‐resistance was found against all four compounds, each with a similar resistance 315 
index of between 4‐5 (Figure 6 c). Following 28 weeks of selection, the morphology of the r22 316 
promastigotes was compared to that of WT (Figure 6 d). The r22 strain appear to have a significant 317 
five‐fold reduction in the mean length of the flagellum (Figure 6 e), suggesting either a fast growth 318 
phenotype or dysfunction in flagellar development [55]. The body area of both promastigotes and 319 
amastigotes was also assessed, noting a small (c 20%) decrease in the body area of r22 parasites 320 
compared to WT strains (Figure S3). While further investigation into the virulence and 321 
transmissibility of this 700022‐resistant line was not performed, shortened flagella do not necessarily 322 
prevent colonisation of the sandfly vector and thus transmissibility might not be compromised 323 
[55,56].  324 
 325 
Figure 6:  Comparison between wildtype and 700022‐resistant (r22) L. mexicana cell lines. Log 326 
concentration versus normalised (compared to untreated control) growth curves for wildtype (WT) 327 
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and corresponding 700022‐selected (r22) L. mexicana A promastigotes and B axenic amastigotes. Error 328 
bars represent upper and lower limits of the StDev (n=9). C Average EC50 of WT and r22 after 8 weeks 329 
of 700022 selection pressure against 700022 and structurally related sterol hits against L. mexicana. The 330 
resistance index (EC50 in r22/EC50 in WT) are shown for each compound. D Scanning electron 331 
micrographs of WT and r22 promastigotes illustrating the shortened flagellum in r22 parasites. E 332 
Analysis of flagellum length in WT and r22 promastigotes (n=287 of each strain) reported using a box 333 
and whisker plot (boxes represents the 25‐75th percent distribution with the mean as a horizontal line, 334 
whiskers represent the distribution of all values) with a statistically significant difference (Mann‐335 
Whitney U test, p‐value<2.2×10‐16). F Mean EC50 of a panel of indicated compounds against WT and 336 
r22 after 28 weeks of 700022‐selection pressure. Error bars represent upper and lower limits of the 337 
StDev (n=9). Miltefosine, Milt (concentration range used against WT and r22 was 0.16 – 20 μM and 338 
1.6 – 50 μM, respectively); Pentamidine, Pent (concentration range used against both WT and r22 was 339 
0.78 – 50 μM); Amphotericin B, Amp B (concentration range used against both WT and r22 was 0.078 – 340 
1.3 μM). The resistance index (EC50 in r22/EC50 in WT) are shown for each compound. 341 
To assess the effect of resistance to 700022 in the r22 line compared to current therapies for 342 
leishmaniasis, the EC50 for amphotericin B, miltefosine and pentamidine were assessed in WT and 343 
r22 lines (Figure 6 f). Whilst there was no apparent change in EC50 for pentamidine and amphotericin 344 
B (resistance indices of 0.75 and 1.22, respectively), there was a significant shift in the miltefosine 345 
resistance index (17.9). A further issue arose from preliminary L. mexicana intramacrophage assays 346 
also suggesting that these four sterols were not as potent at killing the amastigote parasites within 347 
the activated monocyte THP‐1 cell line (Figure S4). Evaluation of the EC50 for 700022 in a L. mexicana 348 
NanoLuc PEST strain [57] reveals that the EC50 in intramacrophage amastigotes is 10.7μM, reducing 349 
the selectivity of this compound over THP‐1 and HepG2 to factors of 1.6 and 2.7, respectively. Whilst 350 
the miltefosine cross‐resistance and reduction in potency against intramacrophage amastigotes 351 
indicates that these sterols are not appropriate for further development, our findings emphasise the 352 
importance of screening hits for cross‐resistance against current therapies at an early stage.  353 
3. Summary 354 
A screen of the PhytoQuest Phytopure temperate plant natural product library revealed a 355 
number of promising hit compounds against the kinetoplastid parasites screened (Figure 7). Further 356 
analysis of a series of leishmanicidal sterols, including the generation of a resistant parasite line, 357 
revealed cross‐resistance with miltefosine, an important frontline therapy with ongoing reports on 358 
the evolution of resistance [19]. As a number of sterols are being explored for their potential as 359 
possible leads against Leishmania spp. [34], this study highlights the importance of including screening 360 
novel compounds against drug‐resistant lines early in the hit‐to‐lead process.  361 
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 362 
Figure 7: Comparison of the PhytoQuest Phytopure library hits across the four parasite species 363 
investigated. All compounds shown have an EC50 ≤1 μM in the respective species reported here. 364 
Compounds reported in black indicates a high selectivity (SI >20) and/or a low cytotoxicity in HepG2 365 
(CC50 >20 μM). Compounds in grey indicates a low selectivity (SI ≤20) and/or toxicity in HepG2 (CC50 366 
≤ 20 μM).  367 
While T. brucei drug discovery for human use has been relatively well developed for many years, 368 
development of therapies against veterinary pathogens such as T. evansi have been neglected. The 369 
lack of overlap between hits with potency against the two Trypanosoma species used here suggests 370 
that drugs developed for HAT may not necessarily readily translate as a treatment for Surra. Much 371 
more fundamental work in the screening of novel candidates that target T. evansi is needed, as well 372 
as further detailed investigation of selectivity using a panel of human and mammalian cell lines. This 373 
study has contributed to this imperative, identifying 700513 and 700144 as highly selective and potent 374 
hits against T. evansi which warrant further investigation.  375 
4. Materials and Methods  376 
4.1 Culture of parasites and human cell lines 377 
L. mexicana strain MNYC/BZ/62/M379 and L. donovani strain LdBOB (a clonal line from strain 378 
MHOM/SD/62/1S‐CL2) were maintained in vitro in the procyclic promastigote stage. Parasites were 379 
cultivated at 26°C in Schneider’s medium (Gibco) pH 7.0 containing 10% FBS, 100 U/mL penicillin 380 
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(Lonza) and 100 μg/mL streptomycin (Lonza) as previously described [57]. Differentiation into axenic 381 
amastigotes was performed as described previously [58]. Briefly, axenic amastigotes were cultivated 382 
at 32°C in Schneider’s medium pH 5.5 containing 10% FBS, 100 U/mL penicillin (Lonza) and 383 
100 μg/mL streptomycin (Lonza). Bloodstream form T. brucei brucei strain Lister 427 and T. evansi 384 
strain Antat 3/3 [59] were maintained in vitro at 37°C with 5% (v/v) CO2 in HMI‐11 medium 385 
supplemented with 10% FBS, as described elsewhere [60,61]. Intraerythrocytic cultures of P. 386 
falciparum Dd2Luc strain [62] were maintained at 37°C in a 1% O2:3% CO2:96% N2 atmosphere in RPMI‐387 
1640 containing 37.5 mM HEPES, 5 mM NaOH, 10 mM D‐glucose, 2 mM L‐glutamine, 100 μM 388 
hypoxanthine, 25 mg/mL gentamicin sulfate, 5% human serum and 5% albumax‐II and 2% 389 
haematocrit erythrocytes [63,64]. When required, cultures were synchronised to ring stages using the 390 
sorbitol lysis method [65]. Preliminary cytotoxicity screening was assessed using HepG2 cells. These 391 
cells were maintained in vitro at 37°C with 5% (v/v) CO2 in DMEM (Sigma) pH 7 supplemented with 392 
10% FBS, 100 U/mL penicillin (Lonza) and 100 μg/mL streptomycin (Lonza), as previously described 393 
[66,67]. The human monocyte cell line THP‐1 [68] was maintained in vitro by culturing at 37°C with 394 
5% (v/v) CO2 in complete RPMI medium (Dutch modified RPMI‐1640 (Gibco) containing 10% FBS 395 
and 2 mM L‐glutamine (Gibco)). Differentiation of THP‐1 cells into macrophages was performed by 396 
seeding 2.5×105 cells/mL in complete RPMI media, supplemented with 20 ng/mL phorbol 12‐397 
myristate 13‐acetate (PMA), followed by incubation at 37°C with 5% (v/v) CO2 for 24 hours [69].  398 
4.2 Screening  399 
The PhytoQuest Phytopure library is a commercially available collection of purified compounds 400 
isolated predominantly from temperate zone plants, with structures confirmed by NMR and mass 401 
spectrometry. The library was provided as 634 non‐polar compounds (1 mg/mL in DMSO). Initial 402 
screening was performed in a 96‐well plate with 200 μL of parasite culture.  The initial screen used 403 
each compound at a final concentration of 2 μM for L. mexicana axenic amastigotes, T. brucei and 404 
P. falciparum, and at 1 μM for T. evansi. L. mexicana axenic amastigotes were plated at 1×106 cells/mL, 405 
incubated for 72 hours, and the Alamar Blue assay was used to assess parasite growth [70]. Each 406 
compound was tested in triplicate, with two biological replicates (n=6). T. brucei and T. evansi were 407 
plated at 1×105 cells/mL for 48 hours, and the Alamar Blue assay was used to assess parasite growth 408 
[70]. Each compound was tested in triplicate with two biological replicates (n=6). Intraerythrocytic 409 
P. falciparum in the trophozoite stage were seeded at 0.5% parasitaemia and 2% haematocrit for 48 410 
hours, and the Malaria SYBR‐Green I fluorescence assay was used to assess parasite growth [71]. Each 411 
compound was tested in duplicate with two biological replicates (n=4). Negative controls comprised 412 
an equivalent volume of DMSO (equivalent of 1% v/v) to normalise the growth data. Data points 413 
>100% growth and <0% growth were tabulated as 100% and 0%, respectively. Some compounds were 414 
not tested in all parasite lines as there was insufficient material remaining.  415 
4.3 Log concentration v normalised response curves to estimate EC50 416 
EC50 values were determined by serial two‐fold dilution of each compound in 96 well plates. 417 
Culture conditions and viability assays were as stated for the initial screen, with some exceptions. 418 
L. mexicana and L. donovani axenic amastigotes were seeded at 2×106 cell/s mL, T. brucei and T. evansi 419 
were seeded at 2×105 cells/mL. For cytotoxicity studies, HepG2 cells were seeded at 1×105 cells/mL, 420 
incubated for 48 hours and viability was assessed using the Alamar Blue assay [66,67]. Differentiated 421 
THP‐1 cells were seeded at 5×104 cells/mL, incubated for 48 hours, and viability was assessed by the 422 
Alamar Blue assay [57]. Normalised growth and viability data (compared to untreated controls) were 423 
plotted against Log10 concentration to estimate EC50 in GraphPad (Prism v6). Bioluminescence 424 
relative rate of kill assays in asexual intraerythrocytic P. falciparum Dd2luc were carried out as 425 
described [52,53,64].  426 
4.4 Generation of 700022-resistant L. mexicana  427 
Pharmaceuticals 2020, 13, x FOR PEER REVIEW 15 of 21 
 
L. mexicana parasites were grown in increasing concentrations of 700022 in a stepwise manner, 428 
as previously described [54]. Briefly, promastigotes were cultivated in a starting concentration of 429 
11.5 μM of 700022 (the EC50 of this compound against WT L. mexicana procyclic promastigotes) and 430 
passaged at this concentration of inhibitor until the growth rate matched that of the WT L. mexicana. 431 
A dose response assay of the newly selected promastigotes was completed as stated above, with the 432 
exception of the seeding density of 1×105 cells/mL. At this point, the drug pressure was increased to 433 
the concentration of the new EC50 value. This process was completed over 28 weeks until the EC50 434 
reached 85.5 μM.  435 
4.5 Morphological analysis 436 
Scanning electron microscopy (SEM) was performed as previously reported. Briefly, WT and r22 437 
L. mexicana promastigote parasites were washed 3 times in serum‐free Schneiders media (pH 7.0) and 438 
once with PBS. Samples were seeded onto poly‐L‐lysine coated 12 mm coverslips, washed once with 439 
PBS and then fixed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate with 2 mM calcium 440 
chloride (pH 7.4) for 2 hours, then processed and imaged as described previously [72].   441 
Cell volume and flagella length was calculated using immunofluorescence microscopy. Wild‐442 
type and r22 L. mexicana promastigote and axenic amastigote parasites were fixed in 4% (w/v) 443 
paraformaldehyde (PFA), adhered to poly‐L‐lysine slides, permeabilised in 0.1% Triton X‐100 in PBS, 444 
blocked with Image iT FX Signal Enhancer (Life Technologies). Cells were probed with anti‐α‐445 
Tubulin diluted 1:250 in PBS followed by anti‐mouse Alexa Fluor 488 diluted 1:200 in PBS. DNA was 446 
stained using 10 μg/mL DAPI, then washed and mounted. Slides were analysed using the EVOS FL 447 
cell imaging system (ThermoFisher Scientific). Flagellum length and body area of >200 randomly 448 
selected parasites (WT and r22) were measured using ImageJ (version 1.48). Statistical analysis was 449 
completed in R; statistical difference was assessed using the Mann‐Whitney U test in the psych 450 
package [73,74]. 451 
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